These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 21092287)
21. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634 [TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150 [TBL] [Abstract][Full Text] [Related]
23. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411 [TBL] [Abstract][Full Text] [Related]
24. Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation. Brearley C; Jaber A; Bertolino M; Priestley A; Seiberling M Int J Clin Pharmacol Ther; 2007 Jun; 45(6):307-18. PubMed ID: 17595888 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers. García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I; BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408 [TBL] [Abstract][Full Text] [Related]
26. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928 [TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. Dahari H; Affonso de Araujo ES; Haagmans BL; Layden TJ; Cotler SJ; Barone AA; Neumann AU J Hepatol; 2010 Sep; 53(3):460-7. PubMed ID: 20561702 [TBL] [Abstract][Full Text] [Related]
28. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929 [TBL] [Abstract][Full Text] [Related]
36. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA; BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687 [TBL] [Abstract][Full Text] [Related]
37. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Foster GR Drugs; 2010; 70(2):147-65. PubMed ID: 20108989 [TBL] [Abstract][Full Text] [Related]